Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김순길 | - |
dc.date.accessioned | 2017-02-27T04:39:52Z | - |
dc.date.available | 2017-02-27T04:39:52Z | - |
dc.date.issued | 2015-06 | - |
dc.identifier.citation | DRUG DESIGN DEVELOPMENT AND THERAPY, v. 9, Page. 2847-2854 | en_US |
dc.identifier.issn | 1177-8881 | - |
dc.identifier.uri | https://www.dovepress.com/efficacy-of-fimasartanhydrochlorothiazide-combination-in-hypertensive--peer-reviewed-article-DDDT | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/25697 | - |
dc.description.abstract | Background: The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg. Methods: Patients with sitting diastolic blood pressure (siDBP) ˃= 90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ˃90 mmHg. Results: Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88 +/- 8.10 mmHg vs 3.38 +/- 7.33, P=0.0008), and the effect persisted at Week 8 (8.67 +/- 9.39 mmHg vs 5.02 +/- 8.27 mmHg, P=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50 +/- 13.76 mmHg vs 5.75 +/- 12.18 mmHg, P=0.0069 and, at Week 8, 13.45 +/- 15.15 mmHg vs 6.84 +/- 13.57 mmHg, P=0.0007). The proportion of patients who achieved a reduction of siDBP. 10 mmHg from baseline and/or a mean siDBP. 90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, P=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups. Conclusion: The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy. | en_US |
dc.description.sponsorship | This research was initiated and financially supported by Boryung Pharmaceutical Co, Ltd, Seoul, Republic of Korea. The sponsor supported the supply of the study drugs, laboratory testing, and data collection and analysis. All authors acted as principal investigators at the study sites, recruited patients, and collected data. The manuscript was prepared, reviewed, and approved by all authors prior to publication. The funding body was not involved in data analysis, data interpretation, or writing up of the results. Dr Rhee has received lecture honoraria from Pfizer Inc, LG Life Sciences Ltd, and Bayer Korea Ltd, and research grants from Boryung Pharmaceutical Co, Ltd and Dong-A Pharmaceutical Co Ltd. Dr Kim has received lecture honoraria from GlaxoSmithKline, Hanmi Pharmaceutical Co, Ltd, and research grant from Merck Sharp & Dohme, LG Life Sciences Ltd, and Boryung Pharmaceutical Co, Ltd. | en_US |
dc.language.iso | en | en_US |
dc.publisher | DOVE MEDICAL PRESS LTD | en_US |
dc.subject | blood pressure | en_US |
dc.subject | antihypertensive | en_US |
dc.subject | angiotensin-converting enzyme inhibitor | en_US |
dc.subject | angiotensin receptor blocker | en_US |
dc.subject | angiotensin II type 1 receptor | en_US |
dc.subject | renin-angiotensin-aldosterone system inhibitor | en_US |
dc.title | Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy | en_US |
dc.type | Article | en_US |
dc.relation.volume | 9 | - |
dc.identifier.doi | 10.2147/DDDT.S82098 | - |
dc.relation.page | 2847-2854 | - |
dc.relation.journal | DRUG DESIGN DEVELOPMENT AND THERAPY | - |
dc.contributor.googleauthor | Rhee, Moo-Yong | - |
dc.contributor.googleauthor | Baek, Sang Hong | - |
dc.contributor.googleauthor | Kim, Weon | - |
dc.contributor.googleauthor | Park, Chang Gyu | - |
dc.contributor.googleauthor | Park, Seung Woo | - |
dc.contributor.googleauthor | Oh, Byung-Hee | - |
dc.contributor.googleauthor | Kim, Sang-Hyun | - |
dc.contributor.googleauthor | Kim, Jae-Joong | - |
dc.contributor.googleauthor | Shin, Joon-Han | - |
dc.contributor.googleauthor | Kim, Soon-Kil | - |
dc.relation.code | 2015012608 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | kimsg | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.